Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Science Daily

Ancient DNA solves 12,000-year-old mystery of rare genetic growth disorder

An Ice Age double burial in Italy has yielded a stunning genetic revelation. DNA from a mother and daughter who lived over 12,000 years ago shows that the younger had a rare inherited growth disorder, ...

Moving biopesticides through plants opens new opportunities

University of Queensland research has revealed that double-stranded RNA-based biopesticides (dsRNA) sprayed on plant leaves can travel right down into root systems. Led by Dr. Chris Brosnan at UQ's ...
Le Lézard

FDA approves RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj). When ...
Nature

Nanoscience is latest discipline to embrace large-scale replication efforts

A European project calls for help to verify whether carbon quantum dots are really able to sense chemicals in cells.
Rochester Institute of Technology

RIT researchers formulate a new “recipe” for 3D bioprinting stronger, human-like tissues

RIT researchers solve multiple tissue engineering challenges by developing a novel hydrogel to host human cells and a device to 3D print bioinks safely.
Le Lézard

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Scinai Immunotherapeutics Ltd.  ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today ...